Trial Profile
Evaluation of Obatoclax Mesylate as Therapy for Patients withSystemic Mastocytosis.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2011
Price :
$35
*
At a glance
- Drugs Obatoclax (Primary)
- Indications Mast Cell Leukemia; Systemic mastocytosis
- Focus Biomarker; Therapeutic Use
- 12 Oct 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 29 May 2010 New source identified and integrated (M.D. Anderson Cancer Center).
- 23 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.